Quantcast
Home > Quotes > ADILW

Adial Pharmaceuticals, Inc Warrant (ADILW) Quote & Summary Data

ADILW 
$0.2
*  
unch
unch
Get ADILW Alerts
*Delayed - data as of Aug. 23, 2019  -  Find a broker to begin trading ADILW now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
Today's High / Low
N/A / N/A
Share Volume
0
50 Day Avg. Daily Volume
N/A
Previous Close
$ 0.20
52 Week High / Low
$ 2.4499 / $ 0.15
Market Cap
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0

Intraday Chart

Shares Traded

Share Volume:
0
50 Day Avg. Daily Volume:
N/A

Trading Range

The current last sale of $0.20 is 33.33% Higher than the 52 week low.

Intraday Last 52 Weeks
High: N/A $ 2.4499
 Low: N/A $ 0.15

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder ("AUD") using our lead investigational new drug product, AD04, a selective serotonin-3 antagonist (i.e., a "5-HT3 antagonist"). The active ingredient in AD04 is ondansetron, which is also the active ingredient in ZofranĀ® , an approved drug for treating nausea and emesis. AUD is characterized by an urge to consume alcohol and an inability to control the levels of consumption. We intend to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes. We believe our approach is unique in that it targets the serotonin system and individualizes the treatment of AUD, through the use of genetic screening.  ... More ...  

Nasdaq Official Price

Open Price:
$ 0.20
Open Date:
Aug. 22, 2019
Close Price:
$ 0.20
Close Date:
Aug. 22, 2019


Research Brokers before you trade

Want to trade FX?

Analyst Info